Fed. Circ. Upholds Ruling Nixing BMS Hepatitis Drug Patent
The Federal Circuit on Wednesday affirmed a lower court's decision that a Bristol-Myers Squibb Co. patent covering the hepatitis B drug Baraclude is invalid as obvious because it made only minor...To view the full article, register now.
Already a subscriber? Click here to view full article